BridgeBio Pharma Inc. (BBIO)

The total asset value of BridgeBio Pharma Inc. (BBIO) stood at $ 757 Mln as on 30-Sep-23

The share price of BridgeBio Pharma Inc. (BBIO) is $28.84 (NASDAQ) as of 28-Nov-2023 16:09 EST. BridgeBio Pharma Inc. (BBIO) has given a return of -16.27% in the last 3 years.

BridgeBio Pharma Inc. (BBIO) has a market capitalisation of $ 5,146 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of BridgeBio Pharma Inc. (BBIO) is 123.68 times as on 24-Nov-2023, a 47.69% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of BridgeBio Pharma Inc. (BBIO) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BridgeBio Pharma Inc. (BBIO) and enter the required number of quantities and click on buy to purchase the shares of BridgeBio Pharma Inc. (BBIO).

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

The CEO & director of Dr. Neil Kumar Ph.D.. is BridgeBio Pharma Inc. (BBIO), and CFO & Sr. VP is Dr. Charles J. Homcy M.D..

The promoters of BridgeBio Pharma Inc. (BBIO) have pledged 0% of the total equity as on Jul-23.

Some of the close peers are:

No, TTM profit after tax of BridgeBio Pharma Inc. (BBIO) was $-278 Mln.